Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Li Auto Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.18 (market cap $8.04B), while Li Auto Inc trades at $12.84 (market cap $12.25B). The key difference: Li Auto Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| BIO | LI | |
|---|---|---|
Market Cap | $8.04B | $12.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $31.80 |
52-Week Low | $241.71 | $11.74 |
Enterprise Value | $7.85B | $1.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Li Auto (LI) trades at $12.18, down 0.66% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025 and faces headwinds from domestic competition and aggressive discounting. Recent news highlights delivery updates and new model launches, but the stock remains under pressure amid broader EV sector challenges.
The outlook is cautious with a consensus price target of $14.80, suggesting potential upside, but risks include profitability concerns, competitive pressures, and volatile cash flows. Recovery hinges on successful execution of the L series and global expansion, with FY2025-2026 seen as trough years before potential improvement from 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
